How have the results of RTOG 1112 influenced your opinion of Y90 and other IR ablative strategies vs SBRT for HCC not amenable to surgery?

My opinion has changed to a fact with RTOG/NRG 1112 (NCT01730937). RTOG/NRG 1112 now provides definitive evidence that treatment of the entire tumor with an adequate dose of radiation has a survival benefit in patients who are TACE refractory or have macrovascular invasion. The controversy now is whether or not this is independent of more recently approved and more effective systemic therapies.

Regarding Y-90, the score is 3/3 negative randomized phase III trials for Y90 and 1/1 randomized trial positive for SBRT in HCC patients using the same control arm in a comparable population of patients. When you also consider that there are also 3/3 negative phase three trials in first line colorectal cancer, it is hard to understand why Y-90 is sti...